Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.
During the 2009 influenza pandemic, a monovalent AS03-adjuvanted vaccine was almost exclusively used in Germany for immunisation against the 2009 pandemic influenza A(H1N1) virus. One-dose vaccination was recommended for all age groups. We applied the screening method for the rapid assessment of vaccine effectiveness (VE) based on reported data of vaccinated and unvaccinated pandemic influenza cases and vaccination coverage estimates. Preliminary results demonstrate excellent VE in persons aged 14-59 years (96.8%; 95% confidence interval (CI): 95.2-97.9) and moderately high VE in those 60 years or older (83.3%; 95% CI: 71.0-90.5).
Wichmann
O
O
Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. WichmannO@rki.de
Stocker
P
P
Poggensee
G
G
Altmann
D
D
Walter
D
D
Hellenbrand
W
W
Krause
G
G
Eckmanns
T
T
D000293:Adolescent; D000328:Adult; D004196:Disease Outbreaks; D005858:Germany / Q000453:epidemiology; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000302:isolation & purification; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000453:epidemiology* / Q000517:prevention & control*; D007407:Interviews as Topic; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
D007252:Influenza Vaccines